The study analysed that the Age-related related macular degeneration therapeutics pipeline comprises of approximately 55 drug candidates, of which five drug candidates are in the Phase III stage, 12 drug candidates are in Phase II stage, 11 drug candidates are in Phase I, 24 drug candidates are in Pre-clinical stage, and there are three drug candidates which are in Discovery stage. Age-related macular degeneration is a disorder that causes loss of vision in a person due to macula damage; macula is that part of an eye, which helps a person to see, it is made up of millions of light-sensing cells which provide sharp and central vision. The Macula is the most sensitive part of the retina and is located at the back side of the eye. Age-related macular degeneration progresses slowly in an individual and can eventually lead to blindness. The most common symptom of Age-related macular degeneration is blurry vision. Various new therapies and advanced technologies are driving the growth of Age-related macular degeneration therapeutics pipeline.
Browse Report Description at: https://www.psmarketresearch.com/market-analysis/age-related-macular-degeneration-therapeutics-pipeline-analysis
Insights on pipeline segments
As per the findings of the research, around 38.0% of drug candidates of Age-related macular degeneration pipeline are being developed to be administered by intra-vitreal route, 9.0% are being developed to be administered by Subretinal route, 6.0% are being developed to be administered by topical route and 4.0% are being developed to be administered by oral route. The share of drug candidates are being developed to be administered by another route such as, subcutaneous injection, eye drop, Intra-ocular, stand at 5%. The percentage share of undisclosed route of administration is 38.0%.
Novel therapy for the development of Age-related macular degeneration therapeutics Pipeline
There are different novel molecule types that are present in the therapeutic pipeline of Age-related macular degeneration which are useful in the treatment of Age-related macular degeneration. Opregen is a drug under the Phase II stage of development, being developed by Cell Cure Neurosciences. Opregen is a stem cells molecule type useful in the treatment of Age-related macular degeneration. Prodexin is a drug present in Phase II stage of development by Taiwan liposome Company. It is a steroid molecule type which shows efficacy to treat Age-related macular degeneration. Apart from Stem cells and steroids molecule type there are different novel molecules types such as monoclonal antibody, gene therapy, enzymes, vitamins, and peptides which are effective in the treatment of Age-related macular degeneration.
Some of the key players developing drugs for Age-related macular degeneration include Formycon, AG, Allergan Plc, Hoffmann-La Roche, Ophthotech Corporation, Regeneron Pharmaceuticals, Inc., Bayer AG, Santen Inc., Ohr Pharmaceutical Inc., Apellis Pharmaceuticals, Inc., Astellas Pharma Inc., SciFluor Life Sciences, Inc., Stealth BioTherapeutics, Inc., Regenxbio Inc., and Iconic Therapeutics, Inc.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY – 10016
Toll-Free: +1-888-778-7886 (USA/Canada)